MX2010003564A - Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso. - Google Patents
Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso.Info
- Publication number
- MX2010003564A MX2010003564A MX2010003564A MX2010003564A MX2010003564A MX 2010003564 A MX2010003564 A MX 2010003564A MX 2010003564 A MX2010003564 A MX 2010003564A MX 2010003564 A MX2010003564 A MX 2010003564A MX 2010003564 A MX2010003564 A MX 2010003564A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor compounds
- parp inhibitor
- relates
- compounds
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos de tetraaza-fenalen-3-ona que inhiben la poli (ADP-ribosa) polimerasa (PARP) y son útiles en la quimiosensibilización de terapia contra el cáncer. La inducción de neuropatía periférica es un efecto secundario común de muchas de las quimioterapias convencionales y de las más nuevas. La presente invención proporciona además medios para impedir de manera confiable curar la neuropatía inducida por quimioterapia. La invención también se refiere al uso de los compuestos inhibidores descritos de PARP en la mejora de la eficiencia de agentes quimioterapéuticos tal como temozolomida. La invención también se refiere al uso de los compuestos inhibidores descritos de PARP para radiosensibilizar células tumorales a la radiación ionizante. La invención también se refiere al uso de los compuestos inhibidores descritos de PARP para tratamiento de cánceres con defectos en la reparación de DNA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97711507P | 2007-10-03 | 2007-10-03 | |
PCT/US2008/078606 WO2009046205A1 (en) | 2007-10-03 | 2008-10-02 | Parp inhibitor compounds, compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010003564A true MX2010003564A (es) | 2010-09-10 |
Family
ID=40526672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010003564A MX2010003564A (es) | 2007-10-03 | 2008-10-02 | Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso. |
Country Status (28)
Country | Link |
---|---|
US (3) | US8236802B2 (es) |
EP (2) | EP2842956A1 (es) |
JP (1) | JP5439380B2 (es) |
KR (1) | KR101596526B1 (es) |
CN (1) | CN102083314B (es) |
AU (1) | AU2008308664B2 (es) |
BR (1) | BRPI0820518B1 (es) |
CA (1) | CA2700903C (es) |
CL (1) | CL2010000320A1 (es) |
CY (1) | CY1115747T1 (es) |
DK (1) | DK2209375T3 (es) |
ES (1) | ES2504690T3 (es) |
HK (1) | HK1146792A1 (es) |
HR (1) | HRP20140853T1 (es) |
IL (1) | IL204776A (es) |
JO (1) | JO3170B1 (es) |
MX (1) | MX2010003564A (es) |
MY (1) | MY155237A (es) |
NZ (1) | NZ585012A (es) |
PL (1) | PL2209375T3 (es) |
PT (1) | PT2209375E (es) |
RU (1) | RU2485122C2 (es) |
SG (1) | SG185272A1 (es) |
SI (1) | SI2209375T1 (es) |
TW (1) | TWI426912B (es) |
UA (1) | UA99483C2 (es) |
WO (1) | WO2009046205A1 (es) |
ZA (1) | ZA201002317B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
JP5439380B2 (ja) | 2007-10-03 | 2014-03-12 | エーザイ インク. | Parp阻害化合物、組成物及び使用方法 |
ES2625817T3 (es) * | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
EP2322658A1 (en) | 2009-11-13 | 2011-05-18 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
KR101826652B1 (ko) * | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
US9649394B2 (en) | 2010-11-22 | 2017-05-16 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
EP2683825B1 (en) * | 2011-03-11 | 2017-01-04 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
TW201244714A (en) * | 2011-04-11 | 2012-11-16 | Abbott Lab | PARP inhibitors for the treatment of CIPN |
WO2012156501A1 (en) | 2011-05-18 | 2012-11-22 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of cancer aggressiveness and genetic instability |
CN103781776A (zh) * | 2011-07-13 | 2014-05-07 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物 |
WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
AU2012358244A1 (en) * | 2011-12-21 | 2014-06-12 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
US9790556B2 (en) | 2012-01-05 | 2017-10-17 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of lung cancer aggressiveness and genetic instability |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
JP6648040B2 (ja) * | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用 |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
US11261466B2 (en) | 2015-03-02 | 2022-03-01 | Sinai Health System | Homologous recombination factors |
CN104945406B (zh) * | 2015-05-25 | 2017-10-10 | 苏州康润医药有限公司 | 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用 |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
US20200230134A1 (en) * | 2017-03-09 | 2020-07-23 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
KR20220079938A (ko) * | 2019-10-10 | 2022-06-14 | 에스테베 파마슈티칼스 에스에이 | 통증에 대한 다중모드 활성을 갖는 호모피페라지닐 및 호모피페리디닐 퀴나졸린-4(3h)-온 유도체 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021249996A1 (en) | 2020-06-08 | 2021-12-16 | Oncology Venture ApS | Compositions comprising 2x-121 and methods for treating coronavirus infection |
CN114053276B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
AU9298098A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US5950784A (en) | 1997-09-03 | 1999-09-14 | Yang; Shu-Chiung C. | Hub structural improvement |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
CA2332279A1 (en) | 1998-05-15 | 1999-11-25 | Jia-He Li | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
SI20691B (sl) | 1999-01-11 | 2008-10-31 | Agouron Pharma | Triciklični inhibitorji poli(ADP-riboza) polimeraz |
WO2001057038A1 (de) | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
CA2517629C (en) * | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7268138B2 (en) | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
MXPA05013145A (es) * | 2003-06-10 | 2006-03-17 | Hoffmann La Roche | Derivados de 1,3,4-triaza-fenaleno y 1,3,4,6-tetraazafenaleno. |
KR101138471B1 (ko) | 2003-07-25 | 2012-04-25 | 화이자 인코포레이티드 | 트리시클로 parp 저해제 |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
CN102107008B (zh) | 2003-12-01 | 2013-04-03 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
JP4964772B2 (ja) | 2004-08-04 | 2012-07-04 | フォスフォニックス リミテッド | 置換有機ポリシロキサン類及びそれらの使用 |
MX2007008771A (es) * | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
JP5439380B2 (ja) | 2007-10-03 | 2014-03-12 | エーザイ インク. | Parp阻害化合物、組成物及び使用方法 |
WO2009137411A1 (en) | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Therapeutic compounds |
CN103097355A (zh) | 2010-07-08 | 2013-05-08 | 惠氏有限责任公司 | 用于治疗皮肤病的新的喹啉酯 |
-
2008
- 2008-10-02 JP JP2010528132A patent/JP5439380B2/ja active Active
- 2008-10-02 UA UAA201005117A patent/UA99483C2/ru unknown
- 2008-10-02 EP EP14179976.7A patent/EP2842956A1/en not_active Withdrawn
- 2008-10-02 SG SG2012073482A patent/SG185272A1/en unknown
- 2008-10-02 AU AU2008308664A patent/AU2008308664B2/en active Active
- 2008-10-02 DK DK08836018.5T patent/DK2209375T3/da active
- 2008-10-02 MY MYPI2010001496A patent/MY155237A/en unknown
- 2008-10-02 NZ NZ585012A patent/NZ585012A/en unknown
- 2008-10-02 CN CN200880118681.4A patent/CN102083314B/zh active Active
- 2008-10-02 PL PL08836018T patent/PL2209375T3/pl unknown
- 2008-10-02 ES ES08836018.5T patent/ES2504690T3/es active Active
- 2008-10-02 BR BRPI0820518-3A patent/BRPI0820518B1/pt active IP Right Grant
- 2008-10-02 US US12/244,399 patent/US8236802B2/en active Active
- 2008-10-02 EP EP08836018.5A patent/EP2209375B1/en active Active
- 2008-10-02 WO PCT/US2008/078606 patent/WO2009046205A1/en active Application Filing
- 2008-10-02 PT PT88360185T patent/PT2209375E/pt unknown
- 2008-10-02 MX MX2010003564A patent/MX2010003564A/es active IP Right Grant
- 2008-10-02 CA CA2700903A patent/CA2700903C/en active Active
- 2008-10-02 KR KR1020107009588A patent/KR101596526B1/ko active IP Right Grant
- 2008-10-02 RU RU2010117397/04A patent/RU2485122C2/ru active
- 2008-10-02 SI SI200831302T patent/SI2209375T1/sl unknown
- 2008-10-03 TW TW097138166A patent/TWI426912B/zh active
- 2008-10-05 JO JOP/2008/0433A patent/JO3170B1/ar active
-
2010
- 2010-03-28 IL IL204776A patent/IL204776A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02317A patent/ZA201002317B/en unknown
- 2010-04-05 CL CL2010000320A patent/CL2010000320A1/es unknown
-
2011
- 2011-01-28 HK HK11100918.6A patent/HK1146792A1/xx unknown
-
2012
- 2012-06-19 US US13/527,158 patent/US8894989B2/en active Active
-
2014
- 2014-09-09 HR HRP20140853AT patent/HRP20140853T1/hr unknown
- 2014-09-25 CY CY20141100783T patent/CY1115747T1/el unknown
- 2014-11-11 US US14/538,447 patent/US20150141429A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010003564A (es) | Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso. | |
IL258880A (en) | Compounds of diarylhydantoin | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
WO2006113703A8 (en) | Carboline derivatives useful in the treatment of cancer | |
MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
WO2008076278A3 (en) | Methods of cancer treatment with igf1r inhibitors | |
SG164368A1 (en) | Treatment of cancer | |
IN2012DN01964A (es) | ||
MX2012010226A (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
MX2009013815A (es) | Compuestos de quinazolinona y metodos de uso para los mismos. | |
CR10450A (es) | Metodo para inhibir la cinasa del c-kit | |
WO2009152228A3 (en) | Use of the combination of phy906 and a tyrosine kinase inhibitor as a cancer treatment regimen | |
MX2010004259A (es) | Tratamientos antitumorales mejorados. | |
MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
WO2008033887A3 (en) | Methods for treating cancer | |
WO2007050564A3 (en) | Boron-containing porphyrin compounds and their uses | |
Du et al. | Expression of Y-box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo | |
MX2009004437A (es) | El uso de un inhibidor de cinasa de multiples objetivos para el tratamiento o la prevencion del cancer cerebral. | |
TW200503798A (en) | Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |